GMP Compliance for Biopharmaceuticals AND GMP for Advanced Therapy Medicinal Products
Im Auftrag der ECA Academy

GMP Compliance for Biopharmaceuticals AND GMP for Advanced Therapy Medicinal Products Im Auftrag der ECA Academy

Berlin, Germany

Seminar Nr. 16321


Kosten

Die Veranstaltung hat bereits stattgefunden. Suchen Sie nach Wiederholungsterminen und weiteren, themenbezogenen Seminaren auf der Seite GMP Seminare/-Konferenzen nach Thema.

Rückfragen unter:
Tel.: 06221 / 84 44 0 E-Mail: info@concept-heidelberg.de

Sprecher

GMP Compliance for Biopharmaceuticals
Dr Markus Fido, Vela Laboratories
Dr Hiltrud Horn, Horn Pharmaceutical Consulting
Stephan Löw, GSK
Dr Daniel Müller, GMP Inspector, German Local Government
Axel Schroeder, Concept Heidelberg

GMP for Advanced Therapy Medicinal Products (ATMP)
Dr Rainer Gnibl, Government of Upper Bavaria
Dr Andrea Hauser, Jose-Carreras Center, University Hospital Regensburg
Dr Hiltrud Horn, Horn Pharmaceutical Consulting
Jan-Oliver Karo, PEI, German Federal Agency for Vaccines and Biomedicines
Dr Ralf Sanzenbacher, Paul-Ehrlich-Institut; German Federal Agency for Vaccines and Biomedicines
Niina Taylor, Pfizer

Programm

GMP Compliance for Biopharmaceuticals


GMP Requirements Applying to Biotechnological Investigational Medicinal Products (IMPs of Clinical Phases I-III & APIs for use in IMPs)
  • EU regulations & guidances
  • Examples of national regulations
  • State-of-the-art manufacturing for clinical phases
GMP Guidelines for Biopharmaceuticals – a brief summary
  • Relevant international regulations
  • European biotech guidances
  • Recent developments & possible impacts
Development of Biopharmaceuticals - GMP and Regulatory Aspects
  • GMP and Regulatory Documents
  • Ways to Success
  • Interaction with Authorities (Meetings/Inspections)
Development, Qualification and Validation of Process Analytics for Biopharmaceuticals
  • Relevant Guidelines
  • Phases of Product Development / Testing
  • Requirements
  • Method Portfolio/Method Development / Method Qualification / Method Validation
GMP Inspections in Biopharmaceutical Production
  • Inspections of biopharmaceutical companies
  • Focus & discussion points during inspections
  • Clean room classes for biotech facilities
  • Open vs. closed processing
  • Single - vs. multi purpose equipment
  • Cell banking activities
  • Inspector’s experience, examples of observations
Case Study: Process Transfer from Development to commercial Production
  • Key-Aspects for EU and US
  • Difference between Development and Commercial Production
  • Case Study
Quality Assurance for Biopharmaceuticals
  • Classical responsibilities of QA department
  • Allocation of responsibilities, training of staff
  • Dealing with suppliers & contractors
  • The world changes: Change management
  • Shit happens: Deviation management & CAPA
  • Handling complaints &product recalls
  • Paper, paper, paper: documentation works: SOPs, MBR, PQR & management report
  • Surveillance of qualification & validation, calibration and maintenance
  • Self inspections & auditing
Process Validation in Clinical Phases I-III
  • Definition of Validation
  • Validation in early Clinical Phase
  • Validation in late Clinical Phase
  • Validation Documentation
  • Guidelines
State-of-the-art biotechnological manufacture (bacteria, yeast, mammalian cells) and cell banking activities - Part 1
  • Reasons for cell banking
  • Where does GMP start
  • Characterization of cell banks
  • Storage of cell banks
State-of-the-art biotechnological manufacture (bacteria, yeast, mammalian cells) and cell banking activities - Part 2
  • Overview of a typical biotech process
  • Requirements on production areas, raw materials
  • and equipment
  • Specialities on biotech products
  • Fill and finish
Workshop:
Case Studies Hygienic GMP Deviations

  • Examples of Pitfalls
  • Chemical Interactions
  • Human Errors
  • Incorrect use
Prevention of cross contamination: dedicated manufacturing or cleaning validation?
  • Requirements of Chapter 3 and 5 and Annex 2
  • Decision with Consequences: Multipurpose
  • Equipment or Disposables
  • Dirt or Product: The Perspective Defines Contamination
  • Ways to Remove Contaminants: Cleaning
  • Procedures and their testing
  • Risk Based Approach: Crucial Element of the Validation Programme

GMP for Advanced Therapy Medicinal Products (ATMP)


Tissues, Tissue Preparations and ATMPs: Introduction
  • Overview on Products and Therapies: Reality and Future
  • Legal Framework in EU and Germany
  • CTA, Hospital Exemption and Marketing Authorisation: Steps to Consider in the Development of ATMPs
The New EU-GMP Guideline for ATMP (Part I)
  • Guideline Overview
  • ATMPs & Quality Risk Management
  • Zone-Concept for ATMP Facility
  • Focus: Qualification & Monitoring
The New EU-GMP Guideline for ATMP (Part II)
  • Focus: Process-Validation & Media Fill
  • Focus: Documentation
  • How to certify/release an ATMP Batch
  • Specific Products/Processes
GMP for ATMP – Considerations to European and US Requirements from industrial point of view
  • Essential Effects of the New Guideline
  • Challenges in Practice
  • US Requirements
Regulatory and Practical Aspects for ATMPs - requirements for QPs
  • Starting materials for ATMPs
  • Raw/ancillary materials for production
  • Specifics for process validation and quality control of ATMPs
  • Responsibilities of the QP - what is different for ATMPs
Requirements on Manufacturing of Cell-based products under GMP
  • Important Aspects for Characterisation and Control
  • Quality of Reagents and Materials
  • Relevant guidance documents
  • Inspection Experiences and Findings
  • Common Deficiencies in Clinical Trial Applications
Case Study – Manufacture of an ATMP for a phase I/II clinical trial in an academic setting
  • Installation of a clean room facility for manufacture of ATMPs in an academic setting
  • Establishment and validation of the manufacturing process with special focus on GMP-compliant FACS sorting
  • Application for a phase I/II investigator initiated clinical trial
GMP Implementation - Practical Industrial Experiences
  • Challenges in aseptic manufacturing
  • Dealing with research grade raw materials in a cGMP environment
  • Dealing with Contract Manufacturing organisations
  • Specific cGMP challenges and possible solutions
Microbiological Safety of ATMPs
  • Challenges and Critical Aspects
  • Relevant Guidance Documents
  • Modern Microbiological Safety Concepts
  • Case Studies from Microbiological Assessment

Zurück

GMP Seminare nach Thema

Cookies helfen uns bei der Bereitstellung unserer Dienste. Durch die Nutzung unserer Dienste erklären Sie sich damit einverstanden, dass wir Cookies setzen. Weitere Informationen

OK